Pharma Mar, S.A. (0RC6.L)

73.87 +0.83 (+1.14%) At close: 06:20PM BST

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
https://www.pharmamar.com

Sector(s): 
Industry: 
Full-time employees: 515

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jose Maria Fernandez Sousa-Faro	Founder, Exec. Chairman, CEO & Pres	294k	N/A	N/A
Mr. Pedro Francisco Fernandez Puentes	Exec. Vice-Chairman	124k	N/A	N/A
Mr. Juan Carlos-Torres Carretero	Founder	N/A	N/A	1949
Ms. María Luisa de Francia Caballero	Chief Financial Officer	N/A	N/A	N/A
Mr. José Luis Moreno Martinez-Losa	Director of Capital Markets & Investor Relations	N/A	N/A	N/A
Mr. Juan Gomez Pulido	Gen. Counsel & Sec. of the Board of Directors	N/A	N/A	N/A
Ms. Sandra Llamera Sanchez	Global Compliance Head	N/A	N/A	N/A
Ms. Lara Vadillo	Communication Director	N/A	N/A	N/A
Mr. Juan Nogues	Director of International Marketing & Sales	N/A	N/A	N/A
Ms. Belén Sopesén Veramendi Ph.D.	Director of Corp. Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Corporate governance

Pharma Mar, S.A.’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.